title: Black pearl in the LIFE study: angiotensin-II receptor blockade on atrial fibrillation for future personalized medicine.
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Ogimoto
authors.forename: Yuji
authors.initials: Y
authors.lastname: Shigematsu
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hara
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Ohtsuka
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Miki
authors.forename: Jitsuo
authors.initials: J
authors.lastname: Higaki
mesh_terms: D001741:Black or African American; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001262:Atenolol / Q000009:adverse effects* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D019808:Losartan / Q000009:adverse effects* / Q000627:therapeutic use; D012008:Recurrence; D044465:White People
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001262:Atenolol; D019808:Losartan